A Narrative Review on the FSTL-1 Protein and its Current Known Impact in Cardiovascular Ischaemic Disease
Keywords:
Myocardial Ischemia, Coronary Artery Disease, FSTL-1, Follistatin-Related Proteins, Follistatin-Related Protein 1Abstract
Myocardial infarction (MI) is one of the leading causes of death worldwide, and even though modern medicine has reduced considerably the number of deaths due to MI, patients still undergo serious cardiac issues that dramatically affects their well-being. Since the start of the century, massive efforts have been employed in exploring stem cell therapy, however, it is believed that it has failed to live up to expectations and further work must done. Alongside this, FSTL-1 has been an emerging protein which seems to offer a multitude of benefits in post-MI. A considerable number of studies with FSTL-1 have been conducted, always with a very satisfactory level of success, especially considering that research is still in its preliminary phases. In this study, a general evaluation is done to 1) the known mechanisms regulated by FSTL-1, 2) the recognized effects of FSTL-1 in cardiac tissue and cells, 3) and what work can be done to clarify questions and further expand our knowledge in order to advance FSTL-1 as a potential therapeutic agent.
References
Rørholm Pedersen, L., Prescott, E., & Kerins, M. (n.d.). ESC prevention of CVD Programme: Epidemiology of IHD. ESC Prevention of CVD Programme: Epidemiology of IHD. Retrieved September 19, 2022, from https://www.escardio.org/Education/ESC-Prevention-of-CVD-Programme/Epidemiology-of-IHD
Urbanek K, Rota M, Cascapera S, Bearzi C, Nascimbene A, De Angelis A, Hosoda T, Chimenti S, Baker M, Limana F, Nurzynska D, Torella D, Rotatori F, Rastaldo R, Musso E, Quaini F, Leri A, Kajstura J, Anversa P. Cardiac stem cells possess growth factor-receptor systems that after activation regenerate the infarcted myocardium, improving ventricular function and long-term survival. Circ Res. 2005 Sep 30;97(7):663-73. doi: 10.1161/01.RES.0000183733.53101.11.
Bartunek J, Behfar A, Dolatabadi D, Vanderheyden M, Ostojic M, Dens J, El Nakadi B, Banovic M, Beleslin B, Vrolix M, Legrand V, Vrints C, Vanoverschelde JL, Crespo-Diaz R, Homsy C, Tendera M, Waldman S, Wijns W, Terzic A. Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J Am Coll Cardiol. 2013 Jun 11;61(23):2329-38. doi: 10.1016/j.jacc.2013.02.071.
Emmert MY, Hitchcock RW, Hoerstrup SP. Cell therapy, 3D culture systems and tissue engineering for cardiac regeneration. Adv Drug Deliv Rev. 2014 Apr;69-70:254-69. doi: 10.1016/j.addr.2013.12.004
van der Spoel TI, Jansen of Lorkeers SJ, Agostoni P, van Belle E, Gyöngyösi M, Sluijter JP, Cramer MJ, Doevendans PA, Chamuleau SA. Human relevance of pre-clinical studies in stem cell therapy: systematic review and meta-analysis of large animal models of ischaemic heart disease. Cardiovasc Res. 2011 Sep 1;91(4):649-58. doi: 10.1093/cvr/cvr113.
Emmert, M.Y., 2017. Cell-based cardiac regeneration. European Heart Journal 38, 1095–1098.. doi:10.1093/eurheartj/ehx152
Ojha N, Dhamoon AS. Myocardial Infarction. 2020 Nov 21. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–. PMID: 30725761.
Jugdutt BI. Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough? Circulation. 2003 Sep 16;108(11):1395-403. doi: 10.1161/01.CIR.0000085658.98621.49.
Nahrendorf M, Swirski FK, Aikawa E, Stangenberg L, Wurdinger T, Figueiredo JL, Libby P, Weissleder R, Pittet MJ. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med. 2007 Nov 26;204(12):3037-47. doi: 10.1084/jem.20070885.
Santini MP, Tsao L, Monassier L, Theodoropoulos C, Carter J, Lara-Pezzi E, Slonimsky E, Salimova E, Delafontaine P, Song YH, Bergmann M, Freund C, Suzuki K, Rosenthal N. Enhancing repair of the mammalian heart. Circ Res. 2007 Jun 22;100(12):1732-40. doi: 10.1161/CIRCRESAHA.107.148791.
Pepper MS, Belin D, Montesano R, Orci L, Vassalli JD. Transforming growth factor-beta 1 modulates basic fibroblast growth factor-induced proteolytic and angiogenic properties of endothelial cells in vitro. J Cell Biol. 1990 Aug;111(2):743-55. doi: 10.1083/jcb.111.2.743.
Shiojima I, Walsh K. Regulation of cardiac growth and coronary angiogenesis by the Akt/PKB signaling pathway. Genes Dev. 2006 Dec 15;20(24):3347-65. doi: 10.1101/gad.1492806.
Ouchi N, Oshima Y, Ohashi K, Higuchi A, Ikegami C, Izumiya Y, Walsh K. Follistatin-like 1, a secreted muscle protein, promotes endothelial cell function and revascularization in ischemic tissue through a nitric-oxide synthase-dependent mechanism. J Biol Chem. 2008 Nov 21;283(47):32802-11. doi: 10.1074/jbc.M803440200.
Ogura Y, Ouchi N, Ohashi K, Shibata R, Kataoka Y, Kambara T, Kito T, Maruyama S, Yuasa D, Matsuo K, Enomoto T, Uemura Y, Miyabe M, Ishii M, Yamamoto T, Shimizu Y, Walsh K, Murohara T. Therapeutic impact of follistatin-like 1 on myocardial ischemic injury in preclinical models. Circulation. 2012 Oct 2;126(14):1728-38. doi: 10.1161/CIRCULATIONAHA.112.115089.
Beauloye C, Bertrand L, Horman S, Hue L. AMPK activation, a preventive therapeutic target in the transition from cardiac injury to heart failure. Cardiovasc Res. 2011 May 1;90(2):224-33. doi: 10.1093/cvr/cvr034.
Oshima, Y., Ouchi, N., Sato, K., Izumiya, Y., Pimentel, D.R., Walsh, K., 2008. Follistatin-Like 1 Is an Akt-Regulated Cardioprotective Factor That Is Secreted by the Heart. Circulation 117, 3099–3108.. doi:10.1161/circulationaha.108.767673
Xi, Y., Gong, D.-W., Tian, Z., 2016. FSTL1 as a Potential Mediator of Exercise-Induced Cardioprotection in Post-Myocardial Infarction Rats. Scientific Reports 6, 32424.. doi:10.1038/srep32424
Yue TL, Wang C, Gu JL, Ma XL, Kumar S, Lee JC, Feuerstein GZ, Thomas H, Maleeff B, Ohlstein EH. Inhibition of extracellular signal-regulated kinase enhances Ischemia/Reoxygenation-induced apoptosis in cultured cardiac myocytes and exaggerates reperfusion injury in isolated perfused heart. Circ Res. 2000 Mar 31;86(6):692-9. doi: 10.1161/01.
Bueno OF, De Windt LJ, Tymitz KM, Witt SA, Kimball TR, Klevitsky R, Hewett TE, Jones SP, Lefer DJ, Peng CF, Kitsis RN, Molkentin JD. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J. 2000 Dec 1;19(23):6341-50. doi: 10.1093/emboj/19.23.6341.
Cai Z, Zhong H, Bosch-Marce M, Fox-Talbot K, Wang L, Wei C, Trush MA, Semenza GL. Complete loss of ischaemic preconditioning-induced cardioprotection in mice with partial deficiency of HIF-1 alpha. Cardiovasc Res. 2008 Feb 1;77(3):463-70. doi: 10.1093/cvr/cvm035.
Muraski JA, Rota M, Misao Y, Fransioli J, Cottage C, Gude N, Esposito G, Delucchi F, Arcarese M, Alvarez R, Siddiqi S, Emmanuel GN, Wu W, Fischer K, Martindale JJ, Glembotski CC, Leri A, Kajstura J, Magnuson N, Berns A, Beretta RM, Houser SR, Schaefer EM, Anversa P, Sussman MA. Pim-1 regulates cardiomyocyte survival downstream of Akt. Nat Med. 2007 Dec;13(12):1467-75. doi: 10.1038/nm1671.
Maruyama S, Nakamura K, Papanicolaou KN, Sano S, Shimizu I, Asaumi Y, van den Hoff MJ, Ouchi N, Recchia FA, Walsh K. Follistatin-like 1 promotes cardiac fibroblast activation and protects the heart from rupture. EMBO Mol Med. 2016 Aug 1;8(8):949-66. doi: 10.15252/emmm.201506151.
Sorescu GP, Song H, Tressel SL, Hwang J, Dikalov S, Smith DA, Boyd NL, Platt MO, Lassègue B, Griendling KK, Jo H. Bone morphogenic protein 4 produced in endothelial cells by oscillatory shear stress induces monocyte adhesion by stimulating reactive oxygen species production from a nox1-based NADPH oxidase. Circ Res. 2004 Oct 15;95(8):773-9. doi: 10.1161/01.RES.0000145728.22878.45.
Geng Y, Dong Y, Yu M, et al. Follistatin-like 1 (Fstl1) is a bone morphogenetic protein (BMP) 4 signaling antagonist in controlling mouse lung development. Proceedings of the National Academy of Sciences of the United States of America. 2011 Apr;108(17):7058-7063. DOI: 10.1073/pnas.1007293108.
Formigli L, Manneschi LI, Nediani C, Marcelli E, Fratini G, Orlandini SZ, Perna AM. Are macrophages involved in early myocardial reperfusion injury? Ann Thorac Surg. 2001 May;71(5):1596-602. doi: 10.1016/s0003-4975(01)02400-6.
Zuidema MY, Zhang C. Ischemia/reperfusion injury: The role of immune cells. World J Cardiol. 2010 Oct 26;2(10):325-32. doi: 10.4330/wjc.v2.i10.325.
Pachori AS, Custer L, Hansen D, Clapp S, Kemppa E, Klingensmith J. Bone morphogenetic protein 4 mediates myocardial ischemic injury through JNK-dependent signaling pathway. J Mol Cell Cardiol. 2010 Jun;48(6):1255-65. doi: 10.1016/j.yjmcc.2010.01.010.
Formigli L, Manneschi LI, Nediani C, Marcelli E, Fratini G, Orlandini SZ, Perna AM. Are macrophages involved in early myocardial reperfusion injury? Ann Thorac Surg. 2001 May;71(5):1596-602. doi: 10.1016/s0003-4975(01)02400-6.
Zuidema MY, Zhang C. Ischemia/reperfusion injury: The role of immune cells. World J Cardiol. 2010 Oct 26;2(10):325-32. doi: 10.4330/wjc.v2.i10.325.
Shen, H., Cui, G., Li, Y. et al. Follistatin-like 1 protects mesenchymal stem cells from hypoxic damage and enhances their therapeutic efficacy in a mouse myocardial infarction model. Stem Cell Res Ther 10, 17 (2019). https://doi.org/10.1186/s13287-018-1111-y
Van Wijk, B., Gunst, Q.D., Moorman, A.F.M., Van Den Hoff, M.J.B., 2012. Cardiac Regeneration from Activated Epicardium. PLOS ONE 7, e44692.. doi:10.1371/journal.pone.0044692
Shimano, M., Ouchi, N., Nakamura, K., Van Wijk, B., Ohashi, K., Asaumi, Y., Higuchi, A., Pimentel, D.R., Sam, F., Murohara, T., Van Den Hoff, M.J.B., Walsh, K., 2011. Cardiac myocyte follistatin-like 1 functions to attenuate hypertrophy following pressure overload. Proceedings of the National Academy of Sciences 108, E899–E906.. doi:10.1073/pnas.1108559108
Wei, K., Serpooshan, V., Hurtado, C., Diez-Cuñado, M., Zhao, M., Maruyama, S., Zhu, W., Fajardo, G., Noseda, M., Nakamura, K., Tian, X., Liu, Q., Wang, A., Matsuura, Y., Bushway, P., Cai, W., Savchenko, A., Mahmoudi, M., Schneider, M.D., Van Den Hoff, M.J.B., Butte, M.J., Yang, P.C., Walsh, K., Zhou, B., Bernstein, D., Mercola, M., Ruiz-Lozano, P., 2015. Epicardial FSTL1 reconstitution regenerates the adult mammalian heart. Nature 525, 479–485.. doi:10.1038/nature15372
Chen W, Xia J, Hu P, Zhou F, Chen Y, Wu J, Lei W, Shen Z. Follistatin-like 1 protects cardiomyoblasts from injury induced by sodium nitroprusside through modulating Akt and Smad1/5/9 signaling. Biochem Biophys Res Commun. 2016 Jan 15;469(3):418-23. doi: 10.1016/j.bbrc.2015.12.026.
Pérez-Pomares, J.M., De La Pompa, J.L., 2011. Signaling During Epicardium and Coronary Vessel Development. Circulation Research 109, 1429–1442.. doi:10.1161/circresaha.111.245589
Ellison GM, Vicinanza C, Smith AJ, Aquila I, Leone A, Waring CD, Henning BJ, Stirparo GG, Papait R, Scarfò M, Agosti V, Viglietto G, Condorelli G, Indolfi C, Ottolenghi S, Torella D, Nadal-Ginard B. Adult c-kit(pos) cardiac stem cells are necessary and sufficient for functional cardiac regeneration and repair. Cell. 2013 Aug 15;154(4):827-42. doi: 10.1016/j.cell.2013.07.039.
Hambrock, H.O. , Kaufmann, B., Muller, S., Hanisch, F.G., Nose, K., Paulsson, M., Maurer,P., and Hartmann, U. (2004) Structural characterization of TSC-36/Flik: analysis of two charge isoforms. J. Biol. Chem., 27911727–11735.
Rossdeutsch A, Smart N, Dubé KN, Turner M, Riley PR. Essential role for thymosin β4 in regulating vascular smooth muscle cell development and vessel wall stability. Circ Res. 2012 Aug 3;111(4):e89-102. doi: 10.1161/CIRCRESAHA.111.259846.
Maruyama S, Nakamura K, Papanicolaou KN, Sano S, Shimizu I, Asaumi Y, van den Hoff MJ, Ouchi N, Recchia FA, Walsh K. Follistatin-like 1 promotes cardiac fibroblast activation and protects the heart from rupture. EMBO Mol Med. 2016 Aug 1;8(8):949-66. doi: 10.15252/emmm.201506151.
Smart N, Bollini S, Dubé KN, Vieira JM, Zhou B, Davidson S, Yellon D, Riegler J, Price AN, Lythgoe MF, Pu WT, Riley PR. De novo cardiomyocytes from within the activated adult heart after injury. Nature. 2011 Jun 8;474(7353):640-4. doi: 10.1038/nature10188.
Shrivastava S, Srivastava D, Olson EN, DiMaio JM, Bock-Marquette I. Thymosin beta4 and cardiac repair. Ann N Y Acad Sci. 2010 Apr;1194:87-96. doi: 10.1111/j.1749-6632.2010.05468.x.
Zhou B, Ma Q, Rajagopal S, Wu SM, Domian I, Rivera-Feliciano J, Jiang D, von Gise A, Ikeda S, Chien KR, Pu WT. Epicardial progenitors contribute to the cardiomyocyte lineage in the developing heart. Nature. 2008 Jul 3;454(7200):109-13. doi: 10.1038/nature07060.
Cao J, Poss KD. The epicardium as a hub for heart regeneration. Nat Rev Cardiol. 2018 Oct;15(10):631-647. doi: 10.1038/s41569-018-0046-4. PMID: 29950578
Görgens SW, Raschke S, Holven KB, Jensen J, Eckardt K, Eckel J. Regulation of follistatin-like protein 1 expression and secretion in primary human skeletal muscle cells. Arch Physiol Biochem. 2013 May;119(2):75-80. doi: 10.3109/13813455.2013.768270.
Miyabe, M., Ohashi, K., Shibata, R., Uemura, Y., Ogura, Y., Yuasa, D., Kambara, T., Kataoka, Y., Yamamoto, T., Matsuo, K., Joki, Y., Enomoto, T., Hayakawa, S., Hiramatsu-Ito, M., Ito, M., Van Den Hoff, M.J.B., Walsh, K., Murohara, T., Ouchi, N., 2014. Muscle-derived follistatin-like 1 functions to reduce neointimal formation after vascular injury. Cardiovascular Research 103, 111–120.. doi:10.1093/cvr/cvu105
Xi, Y., Gong, D.-W., Tian, Z., 2016. FSTL1 as a Potential Mediator of Exercise-Induced Cardioprotection in Post-Myocardial Infarction Rats. Scientific Reports 6, 32424.. doi:10.1038/srep32424
Kambara, T., Ohashi, K., Shibata, R., Ogura, Y., Maruyama, S., Enomoto, T., Uemura, Y., Shimizu, Y., Yuasa, D., Matsuo, K., Miyabe, M., Kataoka, Y., Murohara, T., Ouchi, N., 2012. CTRP9 Protein Protects against Myocardial Injury following Ischemia-Reperfusion through AMP-activated Protein Kinase (AMPK)-dependent Mechanism. Journal of Biological Chemistry 287, 18965–18973.. doi:10.1074/jbc.m112.357939
Miao, C., Lei, M., Hu, W., Han, S., Wang, Q., 2017. A brief review: the therapeutic potential of bone marrow mesenchymal stem cells in myocardial infarction. Stem Cell Research & Therapy 8.. doi:10.1186/s13287-017-0697-9
Downloads
Published
How to Cite
License
Copyright (c) 2024 José Rodrigues Gomes, Mário Santos
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- The Author retains copyright in the Work, where the term “Work” shall include all digital objects that may result in subsequent electronic publication or distribution.
- Upon acceptance of the Work, the author shall grant to the Publisher the right of first publication of the Work.
- The Author shall grant to the Publisher and its agents the nonexclusive perpetual right and license to publish, archive, and make accessible the Work in whole or in part in all forms of media now or hereafter known under a Creative Commons Attribution 4.0 International License or its equivalent, which, for the avoidance of doubt, allows others to copy, distribute, and transmit the Work under the following conditions:
- Attribution—other users must attribute the Work in the manner specified by the author as indicated on the journal Web site; with the understanding that the above condition can be waived with permission from the Author and that where the Work or any of its elements is in the public domain under applicable law, that status is in no way affected by the license.
- The Author is able to enter into separate, additional contractual arrangements for the nonexclusive distribution of the journal's published version of the Work (e.g., post it to an institutional repository or publish it in a book), as long as there is provided in the document an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post online a prepublication manuscript (but not the Publisher’s final formatted PDF version of the Work) in institutional repositories or on their Websites prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. Any such posting made before acceptance and publication of the Work shall be updated upon publication to include a reference to the Publisher-assigned DOI (Digital Object Identifier) and a link to the online abstract for the final published Work in the Journal.
- Upon Publisher’s request, the Author agrees to furnish promptly to Publisher, at the Author’s own expense, written evidence of the permissions, licenses, and consents for use of third-party material included within the Work, except as determined by Publisher to be covered by the principles of Fair Use.
- The Author represents and warrants that:
- the Work is the Author’s original work;
- the Author has not transferred, and will not transfer, exclusive rights in the Work to any third party;
- the Work is not pending review or under consideration by another publisher;
- the Work has not previously been published;
- the Work contains no misrepresentation or infringement of the Work or property of other authors or third parties; and
- the Work contains no libel, invasion of privacy, or other unlawful matter.
- The Author agrees to indemnify and hold Publisher harmless from the Author’s breach of the representations and warranties contained in Paragraph 6 above, as well as any claim or proceeding relating to Publisher’s use and publication of any content contained in the Work, including third-party content.
Enforcement of copyright
The IJMS takes the protection of copyright very seriously.
If the IJMS discovers that you have used its copyright materials in contravention of the license above, the IJMS may bring legal proceedings against you seeking reparation and an injunction to stop you using those materials. You could also be ordered to pay legal costs.
If you become aware of any use of the IJMS' copyright materials that contravenes or may contravene the license above, please report this by email to contact@ijms.org
Infringing material
If you become aware of any material on the website that you believe infringes your or any other person's copyright, please report this by email to contact@ijms.org
